

[Request Information](#)

[Permalink](#)

## Treatment to protect and / or recover sexual function of the cavernosal nerve (sexual potency) after radical prostatectomy

Tech ID: 22229 / UC Case 2010-964-0

### BRIEF DESCRIPTION

It is estimated that 1 in 6 men will be diagnosed with prostate cancer in their lifetime. One of the consequences of removing the prostate for prostate cancer is a non-permanent injury of the cavernosal nerve during open radical prostatectomy (RP) or robot-assisted radical prostatectomy (RARP), which may result in post-operative sexual dysfunction. These sexual side effects can severely affect the quality of life for men and their loved ones.

Researchers at the University of California, Irvine have developed a new use for an existing compound that can be used to prevent, mitigate, or treat erectile dysfunction associated with prostate removal surgery.

### SUGGESTED USES

The compound may be used to treat erectile dysfunction in men who have undergone prostatectomy due to prostate cancer.

### PATENT STATUS

Country	Type	Number	Dated	Case
United States Of America	Issued Patent	8,653,057	02/18/2014	2010-964

### CONTACT

Richard Y. Tun  
tunr@uci.edu  
tel: 949-824-3586.



### OTHER INFORMATION

#### KEYWORDS

Sexual dysfunction, Erectile dysfunction, Prostate cancer

#### CATEGORIZED AS

- » **Medical**
  - » Disease: Cancer
  - » Disease: Kidneys and Genito-Urinary System
  - » New Chemical Entities, Drug Leads
  - » Therapeutics

#### RELATED CASES

2010-964-0

**UCI** Beall  
Applied Innovation

5270 California Avenue / Irvine, CA  
92697-7700 / Tel: 949.824.2683



© 2012 - 2014, The Regents of the University of  
California  
[Terms of use](#)  
[Privacy Notice](#)